Search Results - Tim West
- Showing 1 - 9 results of 9
-
1
-
2
-
3
PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma A... by Stephanie M. Eastwood, Matthew R. Meyer, Kristopher M. Kirmess, Traci L. Wente-Roth, Faith Irvin, Mary S. Holubasch, Philip B. Verghese, Tim West, Joel B. Braunstein, Kevin E. Yarasheski, John H. Contois
Published in Diagnostics (2024-08-01)Get full text
Article -
4
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Pos... by Douglas Galasko, Martin R. Farlow, Brendan P. Lucey, Lawrence S. Honig, Donald Elbert, Randall Bateman, Jeremiah Momper, Ronald G. Thomas, Robert A. Rissman, Judy Pa, Vahan Aslanyan, Archana Balasubramanian, Tim West, Maria Maccecchini, Howard H. Feldman
Published in Alzheimer’s Research & Therapy (2024-07-01)Get full text
Article -
5
Clinical Utility of an Alzheimer’s Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study by Mark Monane, Demetrius M. Maraganore, Robert M. Carlile, Kim G. Johnson, David A. Merrill, Darren R. Gitelman, Kenneth S. Sharlin, Lawren A. VandeVrede, Kristi K. George, Jimin Wang, Tim West, Leslie Jacobs, Philip B. Verghese, Joel B. Braunstein
Published in Diagnostics (2025-01-01)Get full text
Article -
6
A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment by Mark Monane, Kim G. Johnson, B. Joy Snider, Raymond S. Turner, Jonathan D. Drake, Demetrius M. Maraganore, James L. Bicksel, Daniel H. Jacobs, Julia L. Ortega, Joni Henderson, Yan Jiang, Shuguang Huang, Justine Coppinger, Ilana Fogelman, Tim West, Joel B. Braunstein
Published in Annals of Clinical and Translational Neurology (2023-10-01)Get full text
Article -
7
Independent study demonstrates amyloid probability score accurately indicates amyloid pathology by Ilana Fogelman, Tim West, Joel B. Braunstein, Philip B. Verghese, Kristopher M. Kirmess, Matthew R. Meyer, John H. Contois, Eli Shobin, Kyle L. Ferber, Jake Gagnon, Carrie E. Rubel, Danielle Graham, Randall J. Bateman, David M. Holtzman, Shuguang Huang, Joanne Yu, Sha Yang, Kevin E. Yarasheski
Published in Annals of Clinical and Translational Neurology (2023-05-01)Get full text
Article -
8
Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40 by Julie K. Wisch, Brian A. Gordon, Anna H. Boerwinkle, Patrick H. Luckett, James G. Bollinger, Vitaliy Ovod, Yan Li, Rachel L. Henson, Tim West, Mathew R. Meyer, Kristopher M. Kirmess, Tammie L.S. Benzinger, Anne M. Fagan, John C. Morris, Randall J. Bateman, Beau M. Ances, Suzanne E. Schindler
Published in Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring (2023-01-01)Get full text
Article -
9
Plasma Aβ42/40 and cognitive variability are associated with cognitive function in Black Americans: Findings from the AA‐FAIM cohort by Barbara Fischer, Carol Ann Van Hulle, Rebecca Langhough, Derek Norton, Megan Zuelsdorff, Diane Carol Gooding, Mary F. Wyman, Adrienne Johnson, Nickolas Lambrou, Taryn James, Shenikqua Bouges, Fabu Phillis Carter, Hector Salazar, Kristopher Kirmess, Mary Holubasch, Matthew Meyer, Venky Venkatesh, Tim West, Philip Verghese, Kevin Yarasheski, Cynthia M. Carlsson, Sterling C. Johnson, Sanjay Asthana, Carey E. Gleason
Published in Alzheimer’s & Dementia: Translational Research & Clinical Interventions (2023-07-01)Get full text
Article